Molecular diagnostics leads to the evolution of pediatric fibrosarcoma treatment

Fibroblastic tumors are a heterogeneous group of soft tissue neoplasms. The treatment of these tumors has always been challenging, given their rarity and heterogeneity. The management was based on surgical excision, and chemotherapy was added in advanced metastatic disease. The rapid development of molecular and genetic diagnostics allowed further understanding of the complexity of fibroblastic tumors and the use of targeted therapies, especially kinase inhibitors (KI). Thanks to them, crippling procedures can be omitted, and the subsequent successful treatment lines are possible. However, many questions are still related to KI and its place in treatment protocols. Researchers debate whether KI can replace chemotherapy in the first line of treatment. The need for recommendations switches the decision to physicians and parents. In this paper, we focus on the benefits and problems of KI in fibrosarcoma treatment in the pediatric population.